{"id":743808,"date":"2013-05-08T07:30:00","date_gmt":"2013-05-08T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/"},"modified":"2023-03-22T00:04:38","modified_gmt":"2023-03-22T04:04:38","slug":"merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/","title":{"rendered":"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the Biologics License Application (BLA) for its<br \/>\n      investigational ragweed pollen (<i>Ambrosia artemisiifolia<\/i>)<br \/>\n      sublingual allergy immunotherapy tablet has been accepted for review by<br \/>\n      the U.S. Food and Drug Administration (FDA). On March 27, Merck<br \/>\n      announced that the FDA had also accepted the BLA for its investigational <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fresearch-and-development-news%2Fmerck-announces-fda-acceptance-biologics-license-applica&#038;esheet=50627561&#038;lan=en-US&#038;anchor=Timothy+grass+pollen+%28Phleum+pratense%29+sublingual+allergy+immunotherapy+tablet&#038;index=1&#038;md5=a0ec389ab189cc78cd44f59fdb0be0c7\">Timothy<br \/>\n      grass pollen (<i>Phleum pratense<\/i>) sublingual allergy immunotherapy<br \/>\n      tablet<\/a>. Merck expects the FDA\u2019s review for both to be completed in<br \/>\n      the first half of 2014.\n    <\/p>\n<p>\n      The BLA for Merck\u2019s investigational ragweed pollen sublingual allergy<br \/>\n      immunotherapy tablet is supported by five studies evaluating the<br \/>\n      efficacy and safety of the tablet in adults, 18 years of age or older,<br \/>\n      with ragweed induced allergic rhinitis (with or without conjunctivitis).\n    <\/p>\n<p>\n      \u201cMerck has a long history of developing new therapies to help patients<br \/>\n      with allergic rhinitis,\u201d said Jeffrey A. Chodakewitz, M.D., senior vice<br \/>\n      president, interim franchise head, Respiratory &#038; Immunology, Merck<br \/>\n      Research Laboratories. \u201cThis regulatory milestone for our<br \/>\n      investigational ragweed pollen sublingual allergy immunotherapy tablet<br \/>\n      represents another step in our continued commitment to offering<br \/>\n      potential new options to allergy specialists and their patients.\u201d\n    <\/p>\n<p>\n      Merck&#8217;s ragweed pollen sublingual allergy immunotherapy tablet is an<br \/>\n      investigational sublingual dissolvable tablet designed to help treat the<br \/>\n      underlying cause of allergic rhinitis by generating an immune response<br \/>\n      to help protect against the targeted allergen. Merck has partnered with<br \/>\n      ALK-Abello to develop its sublingual allergy immunotherapy tablets for<br \/>\n      ragweed pollen, timothy grass pollen and house dust mite in North<br \/>\n      America.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50627561&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=1061d3825d1c83b732525055d62a4bce\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50627561&#038;lan=en-US&#038;anchor=Twitter&#038;index=3&#038;md5=ea35eddcb40fcd61f9147a46e7b4d00b\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50627561&#038;lan=en-US&#038;anchor=Facebook&#038;index=4&#038;md5=4f801059ba2647fda13a9fe542c6b189\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50627561&#038;lan=en-US&#038;anchor=YouTube&#038;index=5&#038;md5=761d94bde708c0b2c58fc01fec3b42bb\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50627561&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=05d3a1918524e639028091e443484d35\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130508005566r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>Robert Consalvo,        908-423-6595<br \/>or<br \/>Investor:<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational ragweed pollen ( Ambrosia artemisiifolia ) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration (FDA). On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen (Phleum pratense) sublingual allergy immunotherapy tablet . Merck expects the FDA\u2019s review for both to be completed in the first half of 2014. The BLA for Merck\u2019s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis (with or without conjunctivitis). \u201cMerck has a long history of developing new therapies to help patients with allergic rhinitis,\u201d said Jeffrey A. Chodakewitz, M.D., senior vice<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-743808","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational ragweed pollen ( Ambrosia artemisiifolia ) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration (FDA). On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen (Phleum pratense) sublingual allergy immunotherapy tablet . Merck expects the FDA\u2019s review for both to be completed in the first half of 2014. The BLA for Merck\u2019s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis (with or without conjunctivitis). \u201cMerck has a long history of developing new therapies to help patients with allergic rhinitis,\u201d said Jeffrey A. Chodakewitz, M.D., senior vice\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:38+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/\",\"name\":\"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-05-08T07:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational ragweed pollen ( Ambrosia artemisiifolia ) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration (FDA). On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen (Phleum pratense) sublingual allergy immunotherapy tablet . Merck expects the FDA\u2019s review for both to be completed in the first half of 2014. The BLA for Merck\u2019s investigational ragweed pollen sublingual allergy immunotherapy tablet is supported by five studies evaluating the efficacy and safety of the tablet in adults, 18 years of age or older, with ragweed induced allergic rhinitis (with or without conjunctivitis). \u201cMerck has a long history of developing new therapies to help patients with allergic rhinitis,\u201d said Jeffrey A. Chodakewitz, M.D., senior vice","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:38+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/","name":"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx","datePublished":"2013-05-08T07:30:00+00:00","dateModified":"2023-03-22T04:04:38+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130508005566r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-ragweed-pollen-sublingual-allergy-immunotherapy-tablet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"40accc93-4642-4d42-8c8b-be4be68a6e54","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743808\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743808"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}